Boothbay Fund Management LLC Has $1.45 Million Holdings in Pulmonx Co. (NASDAQ:LUNG)

Boothbay Fund Management LLC lessened its position in shares of Pulmonx Co. (NASDAQ:LUNG) by 22.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 212,980 shares of the company’s stock after selling 63,206 shares during the period. Boothbay Fund Management LLC’s holdings in Pulmonx were worth $1,446,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Altium Capital Management LLC raised its position in shares of Pulmonx by 63.0% in the 4th quarter. Altium Capital Management LLC now owns 815,000 shares of the company’s stock worth $5,534,000 after acquiring an additional 315,000 shares in the last quarter. Norges Bank acquired a new stake in Pulmonx during the fourth quarter worth approximately $1,027,000. Rock Springs Capital Management LP grew its stake in Pulmonx by 11.7% during the fourth quarter. Rock Springs Capital Management LP now owns 772,151 shares of the company’s stock worth $5,243,000 after purchasing an additional 80,851 shares during the period. Trexquant Investment LP increased its holdings in Pulmonx by 510.1% in the fourth quarter. Trexquant Investment LP now owns 93,700 shares of the company’s stock worth $636,000 after purchasing an additional 78,343 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Pulmonx by 38.7% in the fourth quarter. Renaissance Technologies LLC now owns 220,510 shares of the company’s stock valued at $1,497,000 after buying an additional 61,500 shares during the period. Institutional investors and hedge funds own 91.04% of the company’s stock.

Insider Activity at Pulmonx

In other Pulmonx news, CEO Steven S. Williamson sold 27,689 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $7.14, for a total transaction of $197,699.46. Following the sale, the chief executive officer now directly owns 194,342 shares of the company’s stock, valued at $1,387,601.88. This represents a 12.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Glendon E. French III sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $7.85, for a total transaction of $157,000.00. Following the completion of the transaction, the director now directly owns 991,974 shares of the company’s stock, valued at approximately $7,786,995.90. This trade represents a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 145,660 shares of company stock valued at $1,128,484 over the last ninety days. Corporate insiders own 6.80% of the company’s stock.

Pulmonx Stock Performance

LUNG opened at $5.19 on Tuesday. Pulmonx Co. has a 1-year low of $4.15 and a 1-year high of $10.01. The company has a market cap of $208.88 million, a price-to-earnings ratio of -3.60 and a beta of 0.61. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. The company’s fifty day moving average price is $6.78 and its two-hundred day moving average price is $6.59.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings results on Wednesday, February 19th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.12. The business had revenue of $23.77 million during the quarter, compared to analyst estimates of $22.29 million. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. On average, analysts expect that Pulmonx Co. will post -1.55 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on LUNG shares. Morgan Stanley began coverage on shares of Pulmonx in a research report on Monday, March 10th. They set an “equal weight” rating for the company. Citigroup began coverage on shares of Pulmonx in a research note on Monday, March 10th. They set a “buy” rating on the stock. Jefferies Financial Group began coverage on shares of Pulmonx in a research note on Monday, March 10th. They issued a “buy” rating for the company. Finally, D. Boral Capital assumed coverage on shares of Pulmonx in a research report on Monday, March 10th. They set a “buy” rating and a $17.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Pulmonx has a consensus rating of “Moderate Buy” and an average price target of $12.75.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.